These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 1004531)

  • 41. Naltrexone implants as treatment for heroin dependence: part I.
    Byrne A; Graham G; Hallinan R; Murnion B
    Addict Biol; 2005 Jun; 10(2):201; author reply 201-2. PubMed ID: 16191674
    [No Abstract]   [Full Text] [Related]  

  • 42. Holidays, triggers, and willpower--is there a role for medications? A commentary on "The effects of extended-release naltrexone on holiday drinking in alcohol-dependent patients".
    Rosenbloom DL
    J Subst Abuse Treat; 2009 Jan; 36(1):7. PubMed ID: 19038694
    [No Abstract]   [Full Text] [Related]  

  • 43. Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone.
    Hulse GK; Morris N; Arnold-Reed D; Tait RJ
    Arch Gen Psychiatry; 2009 Oct; 66(10):1108-15. PubMed ID: 19805701
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A review of parenteral sustained-release naltrexone systems.
    Olsen JL; Kincl FA
    NIDA Res Monogr; 1981; 28():187-93. PubMed ID: 6791004
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A sustained release depot for narcotic antagonists.
    Martin WR; Sandquist VL
    Arch Gen Psychiatry; 1974 Jan; 30(1):31-3. PubMed ID: 4808734
    [No Abstract]   [Full Text] [Related]  

  • 46. Interactions between narcotic agonists, partial agonists and antagonists evaluated by schedule-controlled behavior.
    Harris RA
    J Pharmacol Exp Ther; 1980 Jun; 213(3):497-503. PubMed ID: 6110766
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Interaction between naltrexone and oral THC in heavy marijuana smokers.
    Haney M; Bisaga A; Foltin RW
    Psychopharmacology (Berl); 2003 Feb; 166(1):77-85. PubMed ID: 12491025
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mu antagonist and kappa agonist properties of b-funaltrexamine (b-FNA): long lasting spinal antinociception.
    Jiang Q; Heyman JS; Porreca F
    NIDA Res Monogr; 1989; 95():199-205. PubMed ID: 2561827
    [No Abstract]   [Full Text] [Related]  

  • 49. Potential usefulness of single-dose acute physical dependence on and tolerance to morphine for the evaluation of narcotic antagonists.
    Jacob JJ; Barthelemy CD; Tremblay EC; Colombel MC
    Adv Biochem Psychopharmacol; 1973; 8(0):299-318. PubMed ID: 4800176
    [No Abstract]   [Full Text] [Related]  

  • 50. 6beta-naltrexol preferentially antagonizes opioid effects on gastrointestinal transit compared to antinociception in mice.
    Yancey-Wrona JE; Raymond TJ; Mercer HK; Sadée W; Bilsky EJ
    Life Sci; 2009 Sep; 85(11-12):413-20. PubMed ID: 19583969
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Interaction between opiate and 5-HT3 receptor antagonists in the regulation of alcohol intake.
    Le AD; Sellers EM
    Alcohol Alcohol Suppl; 1994; 2():545-9. PubMed ID: 8974381
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Dependence studies on new compounds in the rhesus monkey, rat and mouse (1989).
    Aceto MD; Bowman ER; Harris LS; May EL
    NIDA Res Monogr; 1989; 95():578-631. PubMed ID: 2641054
    [No Abstract]   [Full Text] [Related]  

  • 53. Overriding the blockade of antinociceptive actions of opioids in rats treated with extended-release naltrexone.
    Dean RL; Todtenkopf MS; Deaver DR; Arastu MF; Dong N; Reitano K; O'Driscoll K; Kriksciukaite K; Gastfriend DR
    Pharmacol Biochem Behav; 2008 Jun; 89(4):515-22. PubMed ID: 18342360
    [TBL] [Abstract][Full Text] [Related]  

  • 54. New horizons: sustained release morphine as agonist treatment.
    Woody GE
    Addiction; 2005 Dec; 100(12):1758-9. PubMed ID: 16367974
    [No Abstract]   [Full Text] [Related]  

  • 55. Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone.
    Dunbar JL; Turncliff RZ; Dong Q; Silverman BL; Ehrich EW; Lasseter KC
    Alcohol Clin Exp Res; 2006 Mar; 30(3):480-90. PubMed ID: 16499489
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Predictive value of analgesic assays in mice and rats.
    Taber RI
    Adv Biochem Psychopharmacol; 1973; 8(0):191-211. PubMed ID: 4604927
    [No Abstract]   [Full Text] [Related]  

  • 57. Influence of chronic prenatal and postnatal administration of naltrexone in locomotor activity induced by morphine in mice.
    Medina Jiménez M; Luján Estrada M; Rodríguez R
    Arch Med Res; 1997; 28(1):61-5. PubMed ID: 9078589
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Chronic ulcers caused by injection of substances: healing aided by naltrexone.
    Reece AS
    Arch Dermatol; 2009 Apr; 145(4):375-7. PubMed ID: 19380658
    [No Abstract]   [Full Text] [Related]  

  • 59. Letter To The Editor - Drug Eruption After Sustained Release Naltrexone Pellet Implantation.
    Ak S; Can Gürel Ş
    Turk Psikiyatri Derg; 2020; 31(2):146-147. PubMed ID: 32594504
    [No Abstract]   [Full Text] [Related]  

  • 60. Naltrexone zinc tannate: a prolonged-action narcotic antagonist complex.
    Gray AP; Robinson DS
    J Pharm Sci; 1974 Jan; 63(1):159-61. PubMed ID: 4811279
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.